Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2024 RBC Capital Markets Global Healthcare Conference to be held May 14-15, 2024 in New York, NY. 2024 RBC Capital Markets Global Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsPresent...
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights include the following: Entered into an agreement with Labcorp to sell select assets of BioReference Health. The transaction includes the sale of BioReference Health’s laboratory testing businesses focused on clinical diagnostics and women’s health, excludi...
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today provided a corporate update and reported financial results for the q...
A director at Herbalife Ltd bought 30,000 shares at 9.650USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
A director at Hawthorn Bancshares Inc bought 15,000 shares at 19.626USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register f...
UMH PROPERTIES, INC. REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024 FREEHOLD, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH) reported Total Income for the quarter ended March 31, 2024 of $57.7 million as compared to $52.6 million for the quarter ended March 31, 2023, representing an increase of 10%. Net Loss Attributable to Common Shareholders amounted to $6.3 million or $0.09 per diluted share for the quarter ended March 31, 2024 as compared to a Net Loss of $5.3 million or $0.09 per diluted share for the quarter ended March 31, 2023. ...
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024. Details of the panel discussion are as follow: BTIG Obesity Health ForumPanel Title: CB1 Axis Therapies for ObesityDate: Wednesday, May 8, 2024Presentation Time: 3:00 p.m. ET For further inf...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the Phase 1, first-in-human clinical data from a dose escalation study being carried out by its partner CSPC in China with CRB-701 (SYS6002) has been accepted for presentation at the annual meeting, to be held May 31-June 4, 2024 in Chicago, IL. CRB-701 (SYS6002) is a next-generation antibody-drug-conju...
Hawthorn Bancshares Announces Cash Dividend JEFFERSON CITY, Mo., April 24, 2024 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.19 per common share, payable July 1, 2024 to shareholders of record at the close of business on June 15, 2024, which represents an increase of $0.02 per common share from the prior quarter's dividend. About Hawthorn Bancshares, Inc. Hawthorn Bancshares, Inc., a financial-bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawtho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.